Regulation of the human TRAIL gene

Cancer Biology and Therapy

Volumn 13, Issue 12, 2012, Pages 1143-1151

  Allen, Joshua E ^a   El Deiry, Wafik S ^a  

^a PENN STATE CANCER INSTITUTE   (United States)

Author keywords

Apoptosis; Cell death; DR4; DR5; Gene regulation; TNF; TRAIL

Indexed keywords

ALPHA INTERFERON; APOPTOTIC PROTEASE ACTIVATING FACTOR 1; BETA INTERFERON; CASPASE 10; CASPASE 9; DEATH DOMAIN RECEPTOR SIGNALING ADAPTOR PROTEIN; DEATH RECEPTOR 4; DEATH RECEPTOR 5; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FLICE INHIBITORY PROTEIN; GAMMA INTERFERON; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; HEAT SHOCK TRANSCRIPTION FACTOR 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; OCTAMER TRANSCRIPTION FACTOR 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIGMENT EPITHELIUM DERIVED FACTOR; PROCASPASE 8; PROTEIN BAK; PROTEIN BAX; PROTEIN P53; RECOMBINANT TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; TRANSCRIPTION FACTOR FOXO; TRANSCRIPTION FACTOR NFAT; TRANSCRIPTION FACTOR SP1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND RECEPTOR; UNINDEXED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

APOPTOSIS; BINDING SITE; CANCER GROWTH; CELL DEATH; CHROMATIN IMMUNOPRECIPITATION; COLON CANCER; DNA BINDING; ENZYME ACTIVATION; EPIGENETICS; GEL MOBILITY SHIFT ASSAY; GENE CONTROL; GENE DELETION; GENE EXPRESSION; GENE MUTATION; GENETIC TRANSCRIPTION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOSURVEILLANCE; INTRACELLULAR SIGNALING; KNOCKOUT MOUSE; MITOCHONDRIAL MEMBRANE; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; PROMOTER REGION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RECOMBINANT GENE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE ACTIVATION; UPREGULATION;

APOPTOSIS; GENE EXPRESSION REGULATION; HUMANS; PROMOTER REGIONS, GENETIC; PROTEIN BINDING; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; SIGNAL TRANSDUCTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867125683     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.21354     Document Type: Review

References (95)

1. Wiley SR Sr., Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673-82; PMID:8777713; http://dx.doi.org/10. 1016/1074-7613(95)90057-8.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 1996; 271:12687-90; PMID:8663110; http://dx.doi.org/10.1074/jbc.271.22.12687.
3. Walczak H, Degli-Esposti MA, Johnson RS, Smolak PJ, Waugh JY, Boiani N, et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J 1997; 16:5386-97; PMID:9311998; http://dx.doi.org/10.1093/emboj/16.17.5386.
4. Fanger NA, Maliszewski CR, Schooley K, Griffith TS. Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Exp Med 1999; 190:1155-64; PMID:10523613; http://dx.doi.org/10.1084/jem.190.8.1155.
5. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 1999; 189:1343-54; PMID:10209050; http://dx.doi.org/10.1084/jem.189.8.1343.
6. Kemp TJ, Moore JM, Griffith TS. Human B cells express functional TRAIL/Apo-2 ligand after CpG-containing oligodeoxynucleotide stimulation. J Immunol 2004; 173:892-9; PMID:15240676.
7. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J Exp Med 1998; 188:2375-80; PMID:9858524; http://dx.doi.org/10.1084/jem.188.12.2375.
8. Cassatella MA, Huber V, Calzetti F, Margotto D, Tamassia N, Peri G, et al. Interferon-activated neutrophils store a TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) intracellular pool that is readily mobilizable following exposure to proinflammatory mediators. J Leukoc Biol 2006; 79:123-32; PMID:16244105; http://dx.doi.org/10.1189/jlb.0805431.
9. Kemp TJ, Ludwig AT, Earel JK, Moore JM, Vanoosten RL, Moses B, et al. Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guerin (BCG) results in the release of functional soluble TRAIL/Apo-2L. Blood 2005; 106:3474-82; PMID:16037389; http://dx.doi.org/10.1182/blood-2005-03-1327.
10. Koga Y, Matsuzaki A, Suminoe A, Hattori H, Hara T. Neutrophil-derived TNF-related apoptosis-inducing ligand (TRAIL): a novel mechanism of antitumor effect by neutrophils. Cancer Res 2004; 64:1037-43; PMID:14871835; http://dx.doi.org/10.1158/0008-5472.CAN-03-1808.
11. Ludwig AT, Moore JM, Luo Y, Chen X, Saltsgaver NA, O'Donnell MA, et al. Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity. Cancer Res 2004; 64:3386-90; PMID:15150089; http://dx.doi.org/10.1158/0008-5472.CAN-04-0374.
12. Tecchio C, Huber V, Scapini P, Calzetti F, Margotto D, Todeschini G, et al. IFNalpha-stimulated neutrophils and monocytes release a soluble form of TNF-related apoptosis-inducing ligand (TRAIL/Apo-2 ligand) displaying apoptotic activity on leukemic cells. Blood 2004; 103:3837-44; PMID:14726404; http://dx.doi.org/10.1182/blood-2003-08-2806.
13. Simons MP, Leidal KG, Nauseef WM, Griffith TS. TNF-related apoptosis-inducing ligand (TRAIL) is expressed throughout myeloid development, resulting in a broad distribution among neutrophil granules. J Leukoc Biol 2008; 83:621-9; PMID:18063697; http://dx.doi.org/10.1189/jlb.0707452.
14. Simons MP, Moore JM, Kemp TJ, Griffith TS. Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils. Infect Immun 2007; 75:1265-71; PMID:17194806; http://dx.doi.org/10.1128/IAI.00938-06.
15. Cha S-S, Kim M-S, Choi YH, Sung B-J, Shin NK, Shin H-C, et al. 2.8 A resolution crystal structure of human TRAIL, a cytokine with selective antitumor activity. Immunity 1999; 11:253-61; PMID:10485660; http://dx.doi.org/10.1016/ S1074-7613(00)80100-4.
16. Hymowitz SG, Christinger HW, Fuh G, Ultsch M, O'Connell M, Kelley RF, et al. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5. Mol Cell 1999; 4:563-71; PMID:10549288; http://dx.doi.org/10.1016/S1097-2765(00)80207-5.
17. Wu GS, Burns TF, Zhan Y, Alnemri ES, El-Deiry WS. Molecular cloning and functional analysis of the mouse homologue of the KILLER/DR5 tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor. Cancer Res 1999; 59:2770-5; PMID:10383128.
18. Pan G, Ni J, Wei Y-F, Yu G, Gentz R, Dixit VM. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science 1997; 277:815-8; PMID:9242610; http://dx.doi.org/10.1126/science.277.5327.815.
19. Degli-Esposti MA, Smolak PJ, Walczak H, Waugh J, Huang C-P, DuBose RF, et al. Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family. J Exp Med 1997; 186:1165-70; PMID:9314565; http://dx.doi.org/10.1084/jem.186.7.1165.
20. Mongkolsapaya J, Cowper AE, Xu X-N, Morris G, McMichael AJ, Bell JI, et al. Lymphocyte inhibitor of TRAIL (TNF-related apoptosis-inducing ligand): a new receptor protecting lymphocytes from the death ligand TRAIL. J Immunol 1998; 160:3-6; PMID:9551946.
21. Pan G, Ni J, Yu G, Wei Y-F, Dixit VM. TRUNDD, a new member of the TRAIL receptor family that antagonizes TRAIL signalling. FEBS Lett 1998; 424:41-5; PMID:9537512; http://dx.doi.org/10.1016/S0014-5793(98)00135-5.
22. Marsters SA, Sheridan JP, Pitti RM, Huang A, Skubatch M, Baldwin D, et al. A novel receptor for Apo2L/TRAIL contains a truncated death domain. Curr Biol 1997; 7:1003-6; PMID:9382840; http://dx.doi.org/10.1016/S0960-9822(06) 00422-2.
23. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG. The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity 1997; 7:813-20; PMID:9430226; http://dx.doi.org/10.1016/S1074-7613(00)80399-4.
24. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, Silverman C, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 1998; 273:14363-7; PMID:9603945; http://dx.doi.org/10.1074/jbc.273.23.14363.
25. Eimon PM, Kratz E, Varfolomeev E, Hymowitz SG, Stern H, Zha J, et al. Delineation of the cell-extrinsic apoptosis pathway in the zebrafish. Cell Death Differ 2006; 13:1619-30; PMID:16888647; http://dx.doi.org/10.1038/sj.cdd. 4402015.
26. Mongkolsapaya J, Grimes JM, Chen N, Xu X-N, Stuart DI, Jones EY, et al. Structure of the TRAIL-DR5 complex reveals mechanisms conferring specificity in apoptotic initiation. Nat Struct Biol 1999; 6:1048-53; PMID:10542098; http://dx.doi.org/10.1038/14935.
27. Bodmer J-L, Meier P, Tschopp J, Schneider P. Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL. J Biol Chem 2000; 275:20632-7; PMID:10748154; http://dx.doi.org/10.1074/jbc.M909721199.
28. Pan G, O'Rourke K, Chinnaiyan AM, Gentz R, Ebner R, Ni J, et al. The receptor for the cytotoxic ligand TRAIL. Science 1997; 276:111-3; PMID:9082980; http://dx.doi.org/10.1126/science.276.5309.111.
29. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes-Alnemri T, Cohen GM, Alnemri ES. Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL. J Biol Chem 1997; 272:25417-20; PMID:9325248; http://dx.doi.org/10.1074/jbc.272.41.25417.
30. rd, Jiang W, Meng R, Krantz ID, et al. KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. Nat Genet 1997; 17:141-3; PMID:9326928; http://dx.doi.org/10.1038/ng1097-141.
31. Tartaglia LA, Ayres TM, Wong GHW, Goeddel DV. A novel domain within the 55 kd TNF receptor signals cell death. Cell 1993; 74:845-53; PMID:8397073; http://dx.doi.org/10.1016/0092-8674(93)90464-2.
32. Kischkel FC, Lawrence DA, Tinel A, LeBlanc H, Virmani A, Schow P, et al. Death receptor recruitment of endogenous caspase-10 and apoptosis initiation in the absence of caspase-8. J Biol Chem 2001; 276:46639-46; PMID:11583996; http://dx.doi.org/10.1074/jbc.M105102200.
33. Wang J, Chun HJ, Wong W, Spencer DM, Lenardo MJ. Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci U S A 2001; 98:13884-8; PMID:11717445; http://dx.doi.org/10.1073/pnas.241358198.
34. Sprick MR, Rieser E, Stahl H, Grosse-Wilde A, Weigand MA, Walczak H. Caspase-10 is recruited to and activated at the native TRAIL and CD95 death-inducing signalling complexes in a FADD-dependent manner but can not functionally substitute caspase-8. EMBO J 2002; 21:4520-30; PMID:12198154; http://dx.doi.org/10.1093/emboj/cdf441.
35. Micheau O, Thome M, Schneider P, Holler N, Tschopp J, Nicholson DW, et al. The long form of FLIP is an activator of caspase-8 at the Fas death-inducing signaling complex. J Biol Chem 2002; 277:45162-71; PMID:12215447; http://dx.doi.org/10.1074/jbc.M206882200.
36. Thome M, Tschopp J. Regulation of lymphocyte proliferation and death by FLIP. Nat Rev Immunol 2001; 1:50-8; PMID:11905814; http://dx.doi.org/10.1038/ 35095508.
37. Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 1998; 94:491-501; PMID:9727492; http://dx.doi.org/10.1016/S0092-8674(00)81590-1.
38. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 1998; 94:481-90; PMID:9727491; http://dx.doi.org/10.1016/S0092-8674(00)81589-5.
39. Maas C, Verbrugge I, de Vries E, Savich G, van de Kooij LW, Tait SWG, et al. Smac/DIABLO release from mitochondria and XIAP inhibition are essential to limit clonogenicity of Type I tumor cells after TRAIL receptor stimulation. Cell Death Differ 2010; 17:1613-23; PMID:20395960; http://dx.doi.org/10.1038/cdd. 2010.39.
40. Jost PJ, Grabow S, Gray D, McKenzie MD, Nachbur U, Huang DCS, et al. XIAP discriminates between type I and type II FAS-induced apoptosis. Nature 2009; 460:1035-9; PMID:19626005; http://dx.doi.org/10.1038/nature08229.
41. Albeck JG, Burke JM, Aldridge BB, Zhang M, Lauffenburger DA, Sorger PK. Quantitative analysis of pathways controlling extrinsic apoptosis in single cells. Mol Cell 2008; 30:11-25; PMID:18406323; http://dx.doi.org/10.1016/j. molcel.2008.02.012.
42. Sun X-M, Bratton SB, Butterworth M, MacFarlane M, Cohen GM. Bcl-2 and Bcl-xL inhibit CD95-mediated apoptosis by preventing mitochondrial release of Smac/DIABLO and subsequent inactivation of X-linked inhibitor-of-apoptosis protein. J Biol Chem 2002; 277:11345-51; PMID:11801595; http://dx.doi.org/10. 1074/jbc.M109893200.
43. Gong B, Almasan A. Genomic organization and transcriptional regulation of human Apo2/TRAIL gene. Biochem Biophys Res Commun 2000; 278:747-52; PMID:11095979; http://dx.doi.org/10.1006/bbrc.2000.3872.
44. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol 2002; 168:1356-61; PMID:11801676.
45. Finnberg N, Gruber JJ, Fei P, Rudolph D, Bric A, Kim S-H, et al. DR5 knockout mice are compromised in radiation-induced apoptosis. Mol Cell Biol 2005; 25:2000-13; PMID:15713653; http://dx.doi.org/10.1128/MCB.25.5.2000-2013. 2005.
46. Lamhamedi-Cherradi S-E, Zheng S-J, Maguschak KA, Peschon J, Chen YH. Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice. Nat Immunol 2003; 4:255-60; PMID:12577054; http://dx.doi.org/10.1038/ ni894.
47. Wandinger K-P, Lünemann JD, Wengert O, Bellmann-Strobl J, Aktas O, Weber A, et al. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis. Lancet 2003; 361:2036-43; PMID:12814715; http://dx.doi.org/10.1016/S0140-6736(03)13641- 0.
48. Lub-de Hooge MN, de Vries EGE, de Jong S, Bijl M. Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis 2005; 64:854-8; PMID:15564310; http://dx.doi.org/10.1136/ard.2004. 029058.
49. Schoppet M, Sattler AM, Schaefer JR, Hofbauer LC. Osteoprotegerin (OPG) and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) levels in atherosclerosis. Atherosclerosis 2006; 184:446-7; PMID:16325821; http://dx.doi.org/10.1016/j.atherosclerosis.2005.10.028.
50. Michowitz Y, Goldstein E, Roth A, Afek A, Abashidze A, Ben Gal Y, et al. The involvement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in atherosclerosis. J Am Coll Cardiol 2005; 45:1018-24; PMID:15808757; http://dx.doi.org/10.1016/j.jacc.2004.12.065.
51. Corallini F, Celeghini C, Rizzardi C, Pandolfi A, Di Silvestre S, Vaccarezza M, et al. Insulin down-regulates TRAIL expression in vascular smooth muscle cells both in vivo and in vitro. J Cell Physiol 2007; 212:89-95; PMID:17352408; http://dx.doi.org/10.1002/jcp.21006.
52. Wang Q, Ji Y, Wang X, Evers BM. Isolation and molecular characterization of the 5'-upstream region of the human TRAIL gene. Biochem Biophys Res Commun 2000; 276:466-71; PMID:11027498; http://dx.doi.org/10.1006/bbrc.2000.3512.
53. Kim K-B, Choi Y-H, Kim I-K, Chung C-W, Kim BJ, Park Y-M, et al. Potentiation of Fas- and TRAIL-mediated apoptosis by IFN-gamma in A549 lung epithelial cells: enhancement of caspase-8 expression through IFN-response element. Cytokine 2002; 20:283-8; PMID:12633570; http://dx.doi.org/10.1006/cyto. 2003.2008.
54. Tu Z, Hamalainen-Laanaya HK, Crispe IN, Orloff MS. Synergy between TLR3 and IL-18 promotes IFN-γ dependent TRAIL expression in human liver NK cells. Cell Immunol 2011; 271:286-91; PMID:21802664; http://dx.doi.org/10.1016/ j.cellimm.2011.07.006.
55. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H. Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs. J Exp Med 1999; 189:1451-60; PMID:10224285; http://dx.doi.org/10.1084/jem.189.9.1451.
56. Solis M, Goubau D, Romieu-Mourez R, Genin P, Civas A, Hiscott J. Distinct functions of IRF-3 and IRF-7 in IFN-alpha gene regulation and control of anti-tumor activity in primary macrophages. Biochem Pharmacol 2006; 72:1469-76; PMID:16846591; http://dx.doi.org/10.1016/j.bcp.2006.06.002.
57. Yanase N, Hata K, Shimo K, Hayashida M, Evers BM, Mizuguchi J. Requirement of c-Jun NH2-terminal kinase activation in interferon-alpha-induced apoptosis through upregulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) in Daudi B lymphoma cells. Exp Cell Res 2005; 310:10-21; PMID:16099454; http://dx.doi.org/10.1016/j.yexcr.2005.06.021.
58. Choi EA, Lei H, Maron DJ, Wilson JM, Barsoum J, Fraker DL, et al. Stat1-dependent induction of tumor necrosis factor-related apoptosis-inducing ligand and the cell-surface death signaling pathway by interferon beta in human cancer cells. Cancer Res 2003; 63:5299-307; PMID:14500361.
59. Wang Q, Zhou Y, Weiss HL, Chow C-W, Evers BM. NFATc1 regulation of TRAIL expression in human intestinal cells. PLoS One 2011; 6:e19882; PMID:21603612; http://dx.doi.org/10.1371/journal.pone.0019882.
60. Chan J, Prado-Lourenco L, Khachigian LM, Bennett MR, Di Bartolo BA, Kavurma MM. TRAIL promotes VSMC proliferation and neointima formation in a FGF-2-, Sp1 phosphorylation-, and NFkappaB-dependent manner. Circ Res 2010; 106:1061-71; PMID:20150555; http://dx.doi.org/10.1161/CIRCRESAHA.109.206029.
61. Lin H-H, Lai S-C, Chau L-Y. Heme oxygenase-1/carbon monoxide induces vascular endothelial growth factor expression via p38 kinase-dependent activation of Sp1. J Biol Chem 2011; 286:3829-38; PMID:21115498; http://dx.doi.org/10.1074/jbc.M110.168831.
62. Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, et al. Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells. Nat Med 2005; 11:77-84; PMID:15619633; http://dx.doi.org/10.1038/nm1161.
63. Baetu TM, Kwon H, Sharma S, Grandvaux N, Hiscott J. Disruption of NF-kappaB signaling reveals a novel role for NF-kappaB in the regulation of TNF-related apoptosis-inducing ligand expression. J Immunol 2001; 167:3164-73; PMID:11544302.
64. Matsuda T, Almasan A, Tomita M, Uchihara JN, Masuda M, Ohshiro K, et al. Resistance to Apo2 ligand (Apo2L)/tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis and constitutive expression of Apo2L/TRAIL in human T-cell leukemia virus type 1-infected T-cell lines. J Virol 2005; 79:1367-78; PMID:15650163; http://dx.doi.org/10.1128/JVI.79.3.1367- 1378.2005.
65. Cippitelli M, Fionda C, Di Bona D, Lupo A, Piccoli M, Frati L, et al. The cyclopentenone-type prostaglandin 15-deoxy-delta 12,14-prostaglandin J2 inhibits CD95 ligand gene expression in T lymphocytes: interference with promoter activation via peroxisome proliferator-activated receptor-gamma- independent mechanisms. J Immunol 2003; 170:4578-92; PMID:12707336.
66. Su Z, Xin S, Xu L, Cheng J, Guo J, Li L, et al. The calcineurin B subunit induces TNF-related apoptosis-inducing ligand (TRAIL) expression via CD11b-NF-κB pathway in RAW264.7 macrophages. Biochem Biophys Res Commun 2012; 417:777-83; PMID:22197822; http://dx.doi.org/10.1016/j.bbrc.2011.12.034.
67. Kuribayashi K, Krigsfeld G, Wang W, Xu J, Mayes PA, Dicker DT, et al. TNFSF10 (TRAIL), a p53 target gene that mediates p53-dependent cell death. Cancer Biol Ther 2008; 7:2034-8; PMID:19106633; http://dx.doi.org/10.4161/cbt.7. 12.7460.
68. Unnithan J, Macklis RM. TRAIL induction by radiation in lymphoma patients. Cancer Invest 2004; 22:522-5; PMID:15565809; http://dx.doi.org/10. 1081/CNV-200026397.
69. Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, Shajahan S, et al. Role of tumor necrosis factor-α and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res 2007; 67:11811-20; PMID:18089811; http://dx.doi.org/10.1158/0008-5472.CAN-07-0722.
70. Modur V, Nagarajan R, Evers BM, Milbrandt J. FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 2002; 277:47928-37; PMID:12351634; http://dx.doi.org/10.1074/jbc.M207509200.
71. van Grevenynghe J, Cubas RA, Noto A, DaFonseca S, He Z, Peretz Y, et al. Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J Clin Invest 2011; 121:3877-88; PMID:21926463; http://dx.doi.org/10.1172/JCI59211.
72. Hirose T, Sowa Y, Takahashi S, Saito S, Yasuda C, Shindo N, et al. p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y. Oncogene 2003; 22:7762-73; PMID:14586402; http://dx.doi.org/10.1038/sj.onc.1207091.
73. Ozören N, El-Deiry W. Heat shock protects HCT116 and H460 cells from TRAIL-induced apoptosis. Exp Cell Res 2002; 281:175-81; PMID:12460647; http://dx.doi.org/10.1006/excr.2002.5660.
74. Lund P, Kotova I, Kedinger V, Khanwalkar H, Voltz E, Hahn WC, et al. Transformation-dependent silencing of tumor-selective apoptosis-inducing TRAIL by DNA hypermethylation is antagonized by decitabine. Mol Cancer Ther 2011; 10:1611-23; PMID:21697397; http://dx.doi.org/10.1158/1535-7163.MCT-11-0140.
75. Forrester K, Almoguera C, Han K, Grizzle WE, Perucho M. Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature 1987; 327:298-303; PMID:2438556; http://dx.doi.org/10.1038/327298a0.
76. Bos JL, Fearon ER, Hamilton SR, Verlaan-de Vries M, van Boom JH, van der Eb AJ, et al. Prevalence of ras gene mutations in human colorectal cancers. Nature 1987; 327:293-7; PMID:3587348; http://dx.doi.org/10.1038/327293a0.
77. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, et al. Genetic alterations during colorectal-tumor development. N Engl J Med 1988; 319:525-32; PMID:2841597; http://dx.doi.org/10.1056/NEJM198809013190901.
78. Koornstra JJ, Kleibeuker JH, van Geelen CMM, Rijcken FEM, Hollema H, de Vries EGE, et al. Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas. J Pathol 2003; 200:327-35; PMID:12845629; http://dx.doi.org/10.1002/path.1364.
79. Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2004; 64:3922-7; PMID:15173003; http://dx.doi.org/10.1158/0008-5472.CAN-03-2219.
80. Ho T-C, Chen S-L, Shih S-C, Chang S-J, Yang S-L, Hsieh J-W, et al. Pigment epithelium-derived factor (PEDF) promotes tumor cell death by inducing macrophage membrane tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J Biol Chem 2011; 286:35943-54; PMID:21846721; http://dx.doi.org/10. 1074/jbc.M111.266064.
81. Halaas O, Vik R, Ashkenazi A, Espevik T. Lipopolysaccharide induces expression of APO2 ligand/TRAIL in human monocytes and macrophages. Scand J Immunol 2000; 51:244-50; PMID:10736093; http://dx.doi.org/10.1046/j.1365-3083. 2000.00671.x.
82. Shapiro MB, Senapathy P. RNA splice junctions of different classes of eukaryotes: sequence statistics and functional implications in gene expression. Nucleic Acids Res 1987; 15:7155-74; PMID:3658675; http://dx.doi.org/10.1093/nar/ 15.17.7155.
83. Krieg A, Krieg T, Wenzel M, Schmitt M, Ramp U, Fang B, et al. TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential. Br J Cancer 2003; 88:918-27; PMID:12644830; http://dx.doi.org/10.1038/sj.bjc.6600772.
84. Woods DC, Alvarez C, Johnson AL. Cisplatin-mediated sensitivity to TRAIL-induced cell death in human granulosa tumor cells. Gynecol Oncol 2008; 108:632-40; PMID:18191995; http://dx.doi.org/10.1016/j.ygyno.2007.11.034.
85. Wang P, Lu Y, Li C, Li N, Yu P, Ma D. Novel transcript variants of TRAIL show different activities in activation of NF-κB and apoptosis. Life Sci 2011; 89:839-46; PMID:21952139; http://dx.doi.org/10.1016/j.lfs.2011.09.003.
86. Pal R, Gochhait S, Chattopadhyay S, Gupta P, Prakash N, Agarwal G, et al. Functional implication of TRAIL -716 C/T promoter polymorphism on its in vitro and in vivo expression and the susceptibility to sporadic breast tumor. Breast Cancer Res Treat 2011; 126:333-43; PMID:20443055; http://dx.doi.org/10.1007/ s10549-010-0900-5.
87. Weber A, Wandinger K-P, Mueller W, Aktas O, Wengert O, Grundström E, et al. Identification and functional characterization of a highly polymorphic region in the human TRAIL promoter in multiple sclerosis. J Neuroimmunol 2004; 149:195-201; PMID:15020080; http://dx.doi.org/10.1016/j.jneuroim.2003.12.014.
88. Yan X, Xu L, Qi J, Liang X, Ma C, Guo C, et al. sTRAIL levels and TRAIL gene polymorphisms in Chinese patients with fatty liver disease. Immunogenetics 2009; 61:551-6; PMID:19629467; http://dx.doi.org/10.1007/s00251-009-0389-4.
89. Kikuchi S, Miyagishi R, Fukazawa T, Yabe I, Miyazaki Y, Sasaki H. TNF-related apoptosis inducing ligand (TRAIL) gene polymorphism in Japanese patients with multiple sclerosis. J Neuroimmunol 2005; 167:170-4; PMID:16040132; http://dx.doi.org/10.1016/j.jneuroim.2005.06.021.
90. Gray HL, Sorensen EL, Hunt JS, Ober C. Three polymorphisms in the 3' UTR of the TRAIL (TNF-related apoptosis-inducing ligand) gene. Genes Immun 2001; 2:469-70; PMID:11781716; http://dx.doi.org/10.1038/sj.gene.6363806.
91. Unoki M, Furuta S, Onouchi Y, Watanabe O, Doi S, Fujiwara H, et al. Association studies of 33 single nucleotide polymorphisms (SNPs) in 29 candidate genes for bronchial asthma: positive association a T924C polymorphism in the thromboxane A2 receptor gene. Hum Genet 2000; 106:440-6; PMID:10830912; http://dx.doi.org/10.1007/s004390000267.
92. Huang MP, Gomes MA, Hillert J, Hillert J; Huang W-X. Apoptosis mediators fasL and TRAIL are upregulated in peripheral blood mononuclear cells in MS. Neurology 2000; 55:928-34; PMID:11061246; http://dx.doi.org/10.1212/WNL.55.7. 928.
93. Bos PD, Zhang XHF, Nadal C, Shu W, Gomis RR, Nguyen DX, et al. Genes that mediate breast cancer metastasis to the brain. Nature 2009; 459:1005-9; PMID:19421193; http://dx.doi.org/10.1038/nature08021.
94. Gobbi G, Di Marcantonio D, Micheloni C, Carubbi C, Galli D, Vaccarezza M, et al. TRAIL up-regulation must be accompanied by a reciprocal PKCε down-regulation during differentiation of colonic epithelial cell: implications for colorectal cancer cell differentiation. J Cell Physiol 2012; 227:630-8; PMID:21465464; http://dx.doi.org/10.1002/jcp.22765.
95. Finnberg N, Klein-Szanto AJP, El-Deiry WS. TRAIL-R deficiency in mice promotes susceptibility to chronic inflammation and tumorigenesis. J Clin Invest 2008; 118:111-23; PMID:18079962; http://dx.doi.org/10.1172/JCI29900.